v3.25.4
Significant agreements - Novartis Option and License Agreement & Collaboration Agreement (Details)
 1 Months Ended 12 Months Ended
Sep. 03, 2024
item
Mar. 04, 2024
item
Mar. 01, 2023
item
Mar. 04, 2022
USD ($)
item
Oct. 31, 2025
item
Oct. 31, 2024
USD ($)
Apr. 30, 2023
USD ($)
Dec. 31, 2025
USD ($)
item
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 28, 2023
USD ($)
shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Collaboration revenue               $ 40,374,000 $ 80,001,000 $ 250,008,000  
Contract with Customer, Asset, Net, Current               $ 151,000 676,000    
Option and License Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Number of performance obligations | item       3              
Number of material rights | item       3              
Novartis agreement 2022                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Upfront payment       $ 54,000,000              
Development milestone | 2023 Neurocrine Collaborative Agreement | Minimum                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Number of countries received regulatory approval | item               1      
Novartis Pharma, AG | 2023 Novartis Collaboration Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Number of development and commercialization licenses | item               2      
Upfront payment               $ 80,000,000      
Shares of common stock | shares                     2,145,002
Aggregate purchase price                     $ 20,000,000
Amount of premium               700,000      
Allocation of fixed consideration               80,000,000      
Costs to obtain collaboration agreement                   1,900,000  
Contract expense                   1,900,000  
Contract with customer liability revenue recognized               5,900,000 4,200,000 80,000,000  
Accounts receivable related to reimbursable costs               1,800,000 1,500,000    
Novartis Pharma, AG | Option and License Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Collaboration revenue           $ 15,000,000     15,000,000    
Number of transgenes | item   3                  
Number of novartis target prior not elected license | item       1              
Number of additional targets | item 2   2 1              
Number of targets notified for termination | item         1            
Upfront payment       $ 54,000,000       15,000,000      
Number of options | item       1              
Number of material rights | item       3              
Allocation of transaction price       $ 18,000,000           25,000,000  
Contract with customer liability revenue recognized               0 $ 15,000,000 79,000,000  
Option exercise             $ 25,000,000        
Novartis Pharma, AG | Material rights                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Allocation of transaction price                   $ 54,000,000  
Novartis Pharma, AG | Development, regulatory and commercialization milestone | Option and License Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Aggregate maximum milestone payments to be received from collaborative partner       125,000,000              
Novartis Pharma, AG | Sales milestone | 2023 Novartis Collaboration Agreement | Maximum                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Allocation of variable consideration               775,000,000      
Novartis Pharma, AG | Sales milestone | Option and License Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Aggregate maximum milestone payments to be received from collaborative partner       $ 175,000,000              
Novartis Pharma, AG | Development milestone | 2023 Novartis Collaboration Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Allocation of variable consideration               425,000,000      
Novartis Pharma, AG | SMA Program | Development, regulatory and commercialization milestone | 2023 Novartis Collaboration Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Aggregate maximum milestone payments to be received from collaborative partner               200,000,000      
Novartis Pharma, AG | SMA Program | Sales milestone | 2023 Novartis Collaboration Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Aggregate maximum milestone payments to be received from collaborative partner               400,000,000      
Novartis Pharma, AG | HD Program | 2023 Novartis Collaboration Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Allocation of variable consideration               24,200,000      
Novartis Pharma, AG | HD Program | Development, regulatory and commercialization milestone | 2023 Novartis Collaboration Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Aggregate maximum milestone payments to be received from collaborative partner               225,000,000      
Novartis Pharma, AG | HD Program | Sales milestone | 2023 Novartis Collaboration Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Aggregate maximum milestone payments to be received from collaborative partner               $ 375,000,000      
Novartis Pharma, AG | Discovery Programs 2023 | 2023 Neurocrine Collaborative Agreement | Maximum                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Number of options | item               4      
Novartis Pharma, AG | Direct licensed product | Development, regulatory and commercialization milestone | Option and License Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Aggregate maximum milestone payments to be received from collaborative partner               $ 125,000,000      
Novartis Pharma, AG | Direct licensed product | Sales milestone | Option and License Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Aggregate maximum milestone payments to be received from collaborative partner               $ 175,000,000